DRUG

niclosamide

Tapeworm infections (FDA 1982); broad repurposing pipeline

29 hypotheses across 8 therapeutic domains

CROSS-DOMAIN PATTERN

Same drug, multiple disease domains

niclosamide appears in hypotheses across 8 disease domains: ALS, Alzheimer, Epilepsy, Glioblastoma, Inflammatory bowel disease, Pancreatic cancer, Rheumatoid arthritis, Type 2 diabetes. Shared mediators that recur across at least two of those domains: STAT3, mTOR, S100A4, PD-L1.

Aggregated from the catalog. Biological interpretation of any multi-indication mechanism would require independent validation — this is a structural observation only.

ALL HYPOTHESES

Repurposing candidates for niclosamide

ALS 1

Mediator	Outcome	Score	Tier	Lit. status	Trial
β-catenin	motor neuron degeneration	0.208	Mid	novel signal	none

Alzheimer 2

Mediator	Outcome	Score	Tier	Lit. status	Trial
STAT3	cognitive deficits	0.208	Mid	novel signal	none
STAT3	Alzheimer's disease	0.208	Mid	partial evidence	none

Epilepsy 6

Mediator	Outcome	Score	Tier	Lit. status	Trial
mTOR	mTOR-opathies	0.208	Mid	novel signal	none
STAT3	persistence of reactive glial states	0.208	Mid	novel signal	none
STAT3	imprinting of epileptic activity patterns	0.208	Mid	novel signal	none
STAT3	GABAergic neuron loss	0.208	Mid	novel signal	none
STAT3	general cell loss	0.208	Mid	novel signal	none
mTOR	neuronal spiking activity	0.208	Mid	novel signal	none

Glioblastoma 9

Mediator	Outcome	Score	Tier	Lit. status	Trial
mTOR	glioblastoma	0.312	High	reproduces known	none
S100A4	overall survival	0.269	Mid	reproduces known	none
S100A4	glioblastoma	0.269	Mid	reproduces known	none
PD-L1	overall survival	0.269	Mid	reproduces known	none
S100A4	GBM prognosis	0.269	Mid	novel signal	none
STAT3	glioblastoma progression	0.208	Mid	novel signal	none
PD-L1	worse overall survival	0.208	Mid	novel signal	none
PD-L1	prognosis	0.208	Mid	reproduces known	none
PD-L1	clinical response	0.208	Mid	partial evidence	none

Inflammatory bowel disease 4

Mediator	Outcome	Score	Tier	Lit. status	Trial
PD-L1	colitis	0.269	Mid	partial evidence	completed
STAT3	Crohn's disease	0.208	Mid	novel signal	none
STAT3	DSS-induced colitis	0.208	Mid	novel signal	none
STAT3	UC	0.208	Mid	partial evidence	none

Pancreatic cancer 4

Mediator	Outcome	Score	Tier	Lit. status	Trial
S100A4	pancreatic adenocarcinoma	0.269	Mid	novel signal	none
STAT3	drug resistance	0.208	Mid	reproduces known	none
STAT3	immune escape	0.208	Mid	partial evidence	none
α-SMA	grade I pancreatic cancer	0.208	Mid	novel signal	none

Rheumatoid arthritis 2

Mediator	Outcome	Score	Tier	Lit. status	Trial
STAT3	prurigo nodularis	0.312	High	novel signal	none
STAT3	arthritis	0.208	Mid	reproduces known	completed

Type 2 diabetes 1

Mediator	Outcome	Score	Tier	Lit. status	Trial
mTOR	microvascular complications	0.208	Mid	partial evidence	none

← All drugs